Skip to main content

In-Vitro Diagnostics Market Set to Soar Past USD 106914.16 Billion by 2030

The global In-Vitro Diagnostics market size is expected to reach USD 106914.16 billion by 2030 and exhibit a CAGR of 4.08% in the forecast period (2023−2030), according to Skyquest’s latest research report. The increasing prevalence of chronic diseases and infectious illnesses, growing demand for personalized and precision medicine approaches, and rising geriatric population contributing to higher healthcare needs fuel the market’s growth.

Westford, USA, Aug. 07, 2023 (GLOBE NEWSWIRE) — According to SkyQuest’s latest global research of the In-Vitro Diagnostics market, increased adoption of point-of-care testing for faster results and improved patient care, integration of AI and machine learning for data analysis and pattern recognition, growth of companion diagnostics for targeted therapies, increasing use of liquid biopsy for non-invasive cancer detection, expansion of molecular diagnostics for infectious diseases and genetic disorders, emphasis on lab automation and robotics for enhanced efficiency, rising demand for home-based testing kits, and collaborations between diagnostic companies and pharmaceutical firms for comprehensive patient care solutions are the trends that aid in the market’s growth.

Browse in-depth TOC on “In-Vitro Diagnostics Market”

  • Pages – 157
  • Tables – 133
  • Figures – 77

Get sample copy of this report:

https://www.skyquestt.com/sample-request/in-vitro-diagnostics-market

In vitro diagnostics (IVDs) are medical devices that are used to analyze samples taken from the human body. These samples can include blood, urine, tissue, and other bodily fluids. IVDs are used to diagnose diseases, monitor patient health, and track the effectiveness of treatments.

Prominent Players in In-Vitro Diagnostics Market

  • Abbott
  • Alere
  • bioMérieux
  • Beckman Coulter
  • Becton Dickinson
  • Bio-Rad Laboratories
  • Cepheid
  • Danaher
  • DiaSorin
  • Illumina
  • Instrumentation Laboratory
  • Johnson & Johnson
  • LabCorp
  • Luminex
  • Ortho Clinical Diagnostics
  • PerkinElmer
  • Qiagen
  • Quidel
  • Siemens Healthineers
  • Thermo Fisher Scientific

Browse summary of the report and Complete Table of Contents (ToC):

https://www.skyquestt.com/report/in-vitro-diagnostics-market

Reagents and kits Demand to Grow Substantially in the Forecast Period

Reagents and kits dominate the global online market as these fundamental components are used across various diagnostic tests and technologies. They are required for sample preparation, reaction initiation, and result interpretation in a wide range of diagnostic applications.

Cancer is the Leading Application Segment

In terms of application, Cancer is the leading segment as it remains a major global health concern, with the incidence of various types of cancer on the rise. As the prevalence of cancer increases, the demand for accurate and reliable diagnostic tools to detect and monitor cancer also grows.

North America is the leading Market Due to the Technological Advancements

Region-wise, North America is one of the largest growing markets with a huge emphasis on technological advancements. Factors such as a well-established healthcare infrastructure, significant investment in research and development, and a high prevalence of chronic diseases contribute to the region’s dominance. Additionally, the presence of major diagnostic companies and academic institutions fosters innovation and technological advancements.

A recent report thoroughly analyzes the major players operating within the In-Vitro Diagnostics market. This comprehensive evaluation has considered several crucial factors, such as collaborations, mergers, innovative business policies, and strategies, providing invaluable insights into the key trends and breakthroughs in the market. Additionally, the report has carefully scrutinized the market share of the top segments and presented a detailed geographic analysis. Finally, the report has highlighted the major players in the industry and their ongoing endeavors to develop innovative solutions that cater to the ever-increasing demand for In-Vitro Diagnostics.

Key Developments in In-Vitro Diagnostics Market

  • In January 2023, Danaher, a multinational conglomerate, acquired Beckman Coulter, a leading provider of IVD products and services. The acquisition was valued at $13.6 billion. Danaher said that the acquisition would strengthen its position in the IVD market and expand its product portfolio.
  • In February 2023, QIAGEN, a global leader in molecular diagnostics, acquired Luminex, a provider of multiplexing systems for IVD applications. The acquisition was valued at $1.5 billion. QIAGEN said that the acquisition would strengthen its position in the multiplexing market and expand its product portfolio.

Speak to Analyst for your custom requirements:

https://www.skyquestt.com/speak-with-analyst/in-vitro-diagnostics-market

Key Questions Answered in In-Vitro Diagnostics Market Report

  • What specific growth drivers are projected to impact the market during the forecast period?
  • Can you list the top companies in the market and explain how they have achieved their positions of influence?
  • In what ways do regional trends and patterns differ within the global market, and how might these differences shape the market’s future growth?

Related Reports in SkyQuest’s Library:

Global Neuroendoscopy Devices Market

Global Sciatica Market

Global Veterinary Reference Laboratory Market 

Global Healthcare RFID Market

Global Connected Drug Delivery Devices Market

About Us:

SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email: sales@skyquestt.com

LinkedIn Facebook Twitter

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.